January 16, 2020
Bigfoot Biomedical, a diabetes startup looking to automate insulin delivery via a connected insulin pen, has kicked off its Series C round with an initial tranche of $45 million. The raise is headed once again by Abbott, with prior backers Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management pitching in once again.
Alongside the news of its raise, Bigfoot...
February 20, 2019
Novo Nordisk’s connected insulin pens will integrate with the Abbott Freestyle Libre system, allowing Freestyle Libre users to see data about their insulin alongside their glucose readings, the companies announced this morning.
"Lack of reliable information is a cause of huge frustration for many people with diabetes and their doctors," Anders Dyhr Toft, CVP of commercial innovation at Novo...
March 15, 2018
Keeping track of insulin dosage and figuring out the right injection angle can be a challenge for people living with diabetes. A new company called nGageIT Digital, has just finished validation trials for its new product, iSenz, a smart noninvasive injection monitoring system that aims to help people correctly angle their injections.
“[iSenz] modernized the insulin pen delivery device,” Raj...
October 21, 2016
Medtronic. Dexcom. Abbott. Sanofi. Google. A lot of very large, well-known companies are investing heavily into innovating the diabetes space, and that innovation is exciting. But a disproportionate amount of the innovation around insulin delivery focuses on the insulin pump, a delivery device that’s only used by a small percentage of insulin users. Most insulin users — between 70 and 93 percent...
October 11, 2016
Patients Pending, a London-based health startup founded by one of the co-creators of Skype and his brother, has announced that it will follow up its Timesulin insulin pen cap with a Bluetooth-connected insulin pen cap, which the company hopes will help create smart dosing systems for patients with Type 1 diabetes who don’t use an insulin pump.
“Our hypothesis has been, so much of the investment...